$55.51
-1.74(-3.03%)
Mkt Cap $10.7B
$51.46
$64.08
52-Week Range
At a Glance
AI-generatedRevenue breakdown: Products Excluding ALDURAZYME (47.4%), Product (25.3%), VIMIZIM (6.8%).
8-K
BioMarin Pharmaceutical Inc. announced discontinuation of dosing and enrollment in Phase 2 trials for VOXZOGO in Turner Syndrome, SHOX-deficiency, and Aggrecan (ACAN)-deficiency due to slipped capital femoral epiphysis (SCFE) events in investigator-sponsored trials. Phase 2 CANOPY trials in Noonan syndrome and idiopathic short stature (ISS) without ACAN-deficiency will continue as planned.$10.7B
Market Cap
$3.2B
Revenue
$350M
Net Income
Employees3,040
Fundamentals
How The Business Makes Money
Revenue by Segment
Products Excluding ALDURAZYME47.4%($15.7B)
Product25.3%($8.3B)
VIMIZIM6.8%($2.2B)
VOXZOGO6.5%($2.1B)
NAGLAZYME4.2%($1.4B)
PALYNZIQ3.3%($1.1B)
ALDURAZYME3.2%($1.0B)
BRINEURA1.6%($517M)
KUVAN1.2%($401M)
Royalty And Other0.4%($145M)
ROCTAVIAN0.2%($65M)
Revenue by Geography
US35.8%($2.8B)
Europe30.3%($2.4B)
Rest Of World19.2%($1.5B)
Latin America14.6%($1.1B)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001048477
ISINUS09061G1013
CUSIP09061G101
Phone415 506 6700
Address770 Lindaro Street, San Rafael, CA, 94901, US
SEC EDGAR